This site needs JavaScript to work properly. Please enable it to take advantage of the complete set of features!

Skip to main page content

Add to Collections

Your saved search

Name of saved search:

Search terms:

Test search terms

Would you like email updates of new search results?

Yes
No

Email: (change)

Frequency:

Which day?

Which day?

Report format:

Send at most:

Send even when there aren't any new results

Optional text in email:

Your RSS Feed

Editorial

. 1995 May;153(5):1592-3.

doi: 10.1016/s0022-5347(01)67468-8.

Prostate cancer

PMID: 7714979
DOI: 10.1016/s0022-5347(01)67468-8

Editorial

Prostate cancer

F H Schroeder. J Urol. 1995 May.

. 1995 May;153(5):1592-3.

doi: 10.1016/s0022-5347(01)67468-8.

Author

PMID: 7714979
DOI: 10.1016/s0022-5347(01)67468-8

No abstract available

PubMed Disclaimer

Comment on

TAG-72 expression in primary, metastatic and hormonally treated prostate cancer as defined by monoclonal antibody CC49.
Brenner PC, Rettig WJ, Sanz-Moncasi MP, Reuter V, Aprikian A, Old LJ, Fair WR, Garin-Chesa P. Brenner PC, et al. J Urol. 1995 May;153(5):1575-9. J Urol. 1995. PMID: 7536270
The results of a phase II randomized trial comparing 5-fluorouracil and 5-fluorouracil plus alpha-interferon: observations on the design of clinical trials for androgen-independent prostate cancer.
Daliani DD, Eisenberg PD, Weems J, Lord R, Fueger R, Logothetis CJ. Daliani DD, et al. J Urol. 1995 May;153(5):1587-91. J Urol. 1995. PMID: 7536271 Clinical Trial.
Lewis Y antigen as detected by the monoclonal antibody BR96 is expressed strongly in prostatic adenocarcinoma.
Myers RB, Srivastava S, Grizzle WE. Myers RB, et al. J Urol. 1995 May;153(5):1572-4. J Urol. 1995. PMID: 7714977
Immediate estrogen or estramustine phosphate therapy versus deferred endocrine treatment in nonmetastatic prostate cancer: a randomized multicenter study with 15 years of followup. The South Sweden Prostate Cancer Study Group.
Lundgren R, Nordle O, Josefsson K. Lundgren R, et al. J Urol. 1995 May;153(5):1580-6. J Urol. 1995. PMID: 7714978 Clinical Trial.

Similar articles

[Prostate-specific antigen as a prognostic parameter of treated prostate carcinoma--a reliable tumor marker?].
Knönagel H, Gautschi K, Vonderschmitt DJ, Hauri D. Knönagel H, et al. Helv Chir Acta. 1988 Jul;55(3):333-5. Helv Chir Acta. 1988. PMID: 2459081 German. No abstract available.
[Value of the search for specific prostatic antigens in fixed specimens].
Stouffs M, Wilmus JP, Couvreur Y, Dossogne M. Stouffs M, et al. Acta Urol Belg. 1984;52(4):588-92. Acta Urol Belg. 1984. PMID: 6083718 French. No abstract available.
[Value of the immunohistochemical detection of PSA in the diagnosis of carcinoma of the prostate].
Escaf S, Isorna S, Riesgo I. Escaf S, et al. Arch Esp Urol. 1987 Nov-Dec;40(9):627-31. Arch Esp Urol. 1987. PMID: 2449870 Review. Spanish. No abstract available.
Prostatic origin of metastases: immunoperoxidase localization of prostate-specific antigen.
Ghazizadeh M, Kagawa S, Maebayashi K, Izumi K, Kurokawa K. Ghazizadeh M, et al. Urol Int. 1984;39(1):9-12. doi: 10.1159/000280934. Urol Int. 1984. PMID: 6203202
[Specific antigens in screening and monitoring patients with prostate cancer].
Grigor'ev ME, Stepenskiĭ AB, Lebedev DV. Grigor'ev ME, et al. Urologiia. 2002 Mar-Apr;(2):50-4. Urologiia. 2002. PMID: 12077825 Review. Russian. No abstract available.

See all similar articles

Publication types

Actions
Actions

MeSH terms

Actions
Actions
Actions
Actions
Actions
Actions
Actions

Substances

Actions

LinkOut - more resources

Full Text Sources
Medical
- MedlinePlus Health Information